
Cardiol Therapeutics Expands Phase III Heart Study After Enrollment Milestone
Cardiol Therapeutics has hit its initial 110-patient enrollment target for the MAVERIC Phase III trial ahead of schedule, prompting the steering committee to expand the study to 150 participants. The decision follows a blinded review that revealed fewer pericarditis recurrences among patients than researchers originally anticipated.























